AstraZeneca completes KYM agreement for CMG901
30 March 2023 07:00 BST License agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate, completed AstraZeneca has completed an exclusive global license agreement with KYM Biosciences Inc.[i] for CMG901, a potential first-in-class antibody drug conjugate (ADC) targeting Claudin 18.2, a promising therapeutic target in gastric cancers. CMG901 is currently being evaluated in a Phase I